Pharmaceutical company that originally developed the drug asset now owned by Spruce Biosciences.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about BioMarin Pharmaceutical Inc. in the last 30 days yet.
The 1 sources with the most insights about BioMarin Pharmaceutical Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Viewed as a case study of poor corporate strategy for selling off a valuable asset (now owned by SPRB) to pursue a different drug that ultimately failed. This serves as a cautionary tale about management decisions.
Mentioned as the company that sold a valuable asset to Spruce Biosciences (SPRB), a practice they are known for with assets deemed too small for their portfolio.
Viewed as a case study of poor corporate strategy for selling off a valuable asset (now owned by SPRB) to pursue a different drug that ultimately failed. This serves as a cautionary tale about management decisions.
Mentioned as the company that sold a valuable asset to Spruce Biosciences (SPRB), a practice they are known for with assets deemed too small for their portfolio.
Other assets that creators frequently mention in the same content as BioMarin Pharmaceutical Inc..
The most active sources covering BioMarin Pharmaceutical Inc. (BMRN) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about BioMarin Pharmaceutical Inc. (BMRN) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering BioMarin Pharmaceutical Inc. (BMRN) most frequently also discuss SRPT, CPRX, RGTI, IONQ, QBTS. See the "Discussed alongside" section above for full asset pages.